Forest Laboratories, Positive Results of Memantine Study of Once-Daily Formulation

Feb. 5, 2008 - Forest Laboratories, Inc. (NYSE: FRX) announced preliminary results of a Phase III study of memantine HCl (currently marketed as Namenda(R), a twice-daily immediate- release formulation) in a novel once-daily formulation. The study evaluated the efficacy, safety, and tolerability of an innovative, proprietary, 28 mg memantine extended-release, once-daily formulation compared to placebo in outpatients with moderate to severe Alzheimer's disease currently treated with a cholinesterase inhibitor... Forest Laboratories' Press Release-